Marshall Wace, LLP Inozyme Pharma, Inc. Transaction History

Marshall Wace, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$4.09 - $7.0 $32,212 - $55,132	7,876 Added 6.16%	135,783 $570,000
Q2 2023 Aug 14, 2023	SELL	$4.93 - $6.74 $331,246 - $452,860	-67,190 Reduced 34.44%	127,907 $712,000
Q1 2023 May 15, 2023	BUY	$1.3 - $5.73 $253,626 - $1.12 Million	195,097 New	195,097 $1.12 Million
Q1 2022 May 16, 2022	SELL	$3.87 - $7.55 $139,447 - $272,049	-36,033 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.58 - $11.5 $14,647 - $30,187	2,625 Added 7.86%	36,033 $247,000
Q3 2021 Nov 15, 2021	SELL	$11.12 - $19.4 $75,549 - $131,803	-6,794 Reduced 16.9%	33,408 $387,000
Q2 2021 Aug 13, 2021	SELL	$15.19 - $21.2 $176,371 - $246,153	-11,611 Reduced 22.41%	40,202 $685,000
Q1 2021 May 17, 2021	BUY	$17.77 - $27.9 $920,717 - $1.45 Million	51,813 New	51,813 $1.03 Million
Q4 2020 Feb 16, 2021	SELL	$19.95 - $27.55 $247,739 - $342,115	-12,418 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$17.54 - $30.2 $217,811 - $375,023	12,418 New	12,418 $326,000

53M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $118M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.